Loading
NASDAQHealthcareBiotechnology
Latest quote
$15.46
−$0.17 · -1.09%
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest quote
$15.46
−$0.17 · -1.09%
Regular session · ET · Market data may be delayed.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Day range
Current $15.46
52-week range
Current $15.46
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
71
Bullish
Risk
38
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Day range
Current $15.46
52-week range
Current $15.46
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 18.94M USD |
| Cost of goods sold | — | 306K USD | — | — | — |
| Gross profit | — | −306K USD | — | — | 18.94M USD |
| Research and development | 187.4M USD | 142.9M USD | 148.16M USD | 91.95M USD | 57.75M USD |
| Selling, general, and administrative | 54.25M USD | 53.71M USD | 42.49M USD | 40.19M USD | 29.15M USD |
| Operating expenses | 241.65M USD | 196.61M USD | 191.09M USD | −144.65M USD | 86.9M USD |
| Interest income | 22.21M USD | 29.66M USD | 21.63M USD | 6.61M USD | 477K USD |
| Depreciation and amortization | 311K USD | 306K USD | 310K USD | 93K USD | 53K USD |
| Operating income | −241.65M USD | −196.92M USD | −191.09M USD | 144.65M USD | −67.95M USD |
| Net income | −219.88M USD | −167.38M USD | −153.16M USD | 111.21M USD | −65.57M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$34.75
124.77% upsidePrice history unavailable
High $40.00Average $34.75Low $27.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI43.14M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM24.89M0.03%78.56B USD0.19%$277.57-0.05%
State Street SPDR S&P Biotech ETFXBI19.7M0.20%10.08B USD0.35%$149.29-0.63%
Vanguard Extended Market ETFVXF13.74M0.01%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO7.68M0.04%18B USD0.06%$112.1-0.10%
iShares Biotechnology ETFIBB5.57M0.05%10.4B USD0.44%$200.48-1.41%
Dimensional - US Small Cap ETFDFAS5.35M0.02%33.66B USD0.31%$78.10+0.23%
Fidelity Enhanced Small Cap ETFFESM4.85M0.07%6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
